novo nordisk fda semaglutide asks to prevent compounders from making GLP-1 knockoffs Novo Nordisk secures FDA approval

Quick Answer: GLP-1 receptor agonists are associated with a modest but statistically significant increase in gallbladder disease risk, including gallstones and cholecystitis, affecting approximately 13% of users

They dont have strong cytochrome P450 activitybut acetaminophen induces it

Employers should stay informed about these regulatory changes to manage prescription drug costs and ensure employee medication access

Ozempic Drug same as Wegovy, but usually intended for diabetes

This study suggests that GLP-1 can enhance the function of brown fat, increase heat production in BAT, and reduce body weight in mice by modulating the activity of the sympathetic system through binding with GLP-1R in the center

"How Nature builds the pigments of life" (PDF)